The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors

Authors

  • A. Stengel,

    1. Charité Center for Internal Medicine and Dermatology, Division for General Internal and Psychosomatic Medicine, Charité- Universitätsmedizin Berlin, Berlin, Germany
    Search for more papers by this author
  • M. Mori,

    1. Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Japan
    Search for more papers by this author
  • Y. Taché

    Corresponding author
    • Department of Medicine, CURE Digestive Diseases Research Center and Center for Neurobiology of Stress, Digestive Diseases Division UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
    Search for more papers by this author

  • Supported by German Research Foundation STE 1765/3-1 (A.S.) and Charité University Funding UFF 89-441-176 (A.S.), NIH R01 DK-33061, NIH Center Grant DK-41301 (Animal Core), VA Research Career Scientist (Y.T.), VA Merit Grant (Y.T.).

Address for correspondence: Professor Y Taché, CURE Building 115, Room 117, VA GLA Healthcare System, 11301 Wilshire Blvd, Los Angeles, CA 90073, USA.

E-mail: ytache@mednet.ucla.edu

Summary

Nesfatin-1 was discovered in 2006 and introduced as a potential novel anorexigenic modulator of food intake and body weight. The past years have witnessed increasing evidence establishing nesfatin-1 as a potent physiological inhibitor of food intake and body weight and unravelled nesfatin-1's interaction with other brain transmitters to exert its food consumption inhibitory effect. As observed for other anorexigenic brain neuropeptides, nesfatin-1 is also likely to exert additional, if not pleiotropic, actions in the brain and periphery. Recent studies established the prominent expression of the nesfatin-1 precursor, nucleobindin2 (NUCB2), in the stomach and pancreas, where nesfatin-1 influences endocrine secretion. This review will highlight the current experimental state-of-knowledge on the effects of NUCB2/nesfatin-1 on food intake, body weight and glucose homeostasis. Potential implications in human obesity will be discussed in relation to the evidence of changes in circulating levels of NUCB2/nesfatin-1 in disease states, the occurrence of genetic NUCB2 polymorphisms and – in contrast to several other hormones – the independence of leptin signalling known to be blunted under conditions of chronically increased body weight.

Ancillary